Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. Neelapu, Sattva; L. Locke, Frederick; L. Bartlett, Nancy; J. Lekakis, Lazaros; B. Miklos, David; A. Jacobson, Caron; Braunschweig, Ira; O. Oluwole, Olalekan; Siddiqi, Tanya; Lin, Yi; M. Timmerman, John; J. Stiff, Patrick; W. Friedberg, Jonathan; W. Flinn, Ian; Goy, Andre; T. Hill, Brian; R. Smith, Mitchell; Deol, Abhinav; Farooq, Umar; McSweeney, Peter; Munoz, Javier; Avivi, Irit; E. Castro, Januario; R. Westin, Jason; C. Chavez, Julio; Ghobadi, Armin; V. Komanduri, Krishna; Levy, Ronald; D. Jacobsen, Eric; E. Witzig, Thomas; Reagan, Patrick; Bot, Adrian; Rossi, John; Navale, Lynn; Jiang, Yizhou; Aycock, Jeff; Elias, Meg; Chang, David; Wiezorek, Jeff; Y. Go, William

doi:10.1056/nejmoa1707447

Public

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Shared by NobleBlocks on Dec 10, 2017 • 12:00 AM UTC

Authors:

S. Neelapu

F. Locke

N. Bartlett

Abstract

Background In a phase 1 trial, axicabtagene ciloleucel (axi‐cel), an autologous anti‐CD19 chimeric antigen receptor (CAR) T‐cell therapy, showed efficacy in patients with refractory large B‐cell lymphoma after the failure of conventional therapy. Methods In this multicenter, phase 2 trial, we enroll...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!